August 2024
Galderma’s Nemluvio Receives FDA Approval for Prurigo Nodularis Treatment
Nemluvio, Galderma, FDA Approval, Prurigo Nodularis, IL-31 Inhibitor, Chronic Skin Condition, Itch Treatment
Biopharma Layoff Tracker 2024: FibroGen, Ajinomoto, AN2 Therapeutics and More Cut Staff
Biopharma layoffs, FibroGen, Ajinomoto, AN2 Therapeutics, pharmaceutical industry, job cuts, restructuring
FDA Approves Sandoz and Ascendis Pharma’s Treatments for nAMD and Hypoparathyroidism
FDA approval, Sandoz, Ascendis Pharma, nAMD, hypoparathyroidism, Yorvipath, TransCon PTH
Crown Laboratories to Acquire Botox Rival Revance Therapeutics for $924M
Crown Laboratories, Revance Therapeutics, Botox rival, Daxxify, acquisition, private deal, skincare company
Analysts Uncover Nuances in Avidity’s DMD Data, Highlighting Promising Results
Avidity Biosciences, DMD, Duchenne Muscular Dystrophy, RNA therapy, phase 1/2 data, clinical trials, biotech, pharmaceuticals
Aldeyra’s Reproxalap Demonstrates Efficacy in Reducing Eye Discomfort in New Phase 3 Study
Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection
Exscientia Merges with Recursion to Form AI-Driven Drug Discovery Leader
Exscientia, Recursion, AI drug discovery, merger, precision chemistry, small molecule synthesis, biotech consolidation
Halda Therapeutics Secures $126M to Advance ‘Hold and Kill’ Solid Tumor Drugs into Clinical Trials
Halda Therapeutics, RIPTAC therapeutics, cancer treatment, solid tumors, prostate cancer, breast cancer, clinical trials, Series B extension financing
Ascendis Pharma Secures FDA Approval for YORVIPATH, a Novel Hormone Replacement Therapy for Hypoparathyroidism
Ascendis Pharma, YORVIPATH, FDA approval, hormone replacement therapy, hypoparathyroidism, TransCon PTH, palopegteriparatide
Halda Therapeutics Secures $126M in Series B Funding to Advance Next-Gen Oral TACs
Halda Therapeutics, Series B funding, next-gen oral TACs, biotech, clinical trials, prostate cancer